

BIOCON GROUP

FACT SHEET

March - 2026

BIOCON LIMITED (CONSOLIDATED)

PROFIT & LOSS STATEMENT

(Rs. Crores)

| Particulars | Q4 FY 26 | Q4 FY 25 | Q4 FY 25 Ex-Lena | Variance % | Variance Adj % |
|--|--------------|--------------|---------------------|-------------|-------------------|
| INCOME | | | | | |
| Generics | 847 | 1,048 | 748 | -19% | 13% |
| Biosimilars | 2,756 | 2,463 | 2,463 | 12% | 12% |
| CRDMO* | 1,037 | 1,018 | 1,018 | 2% | 2% |
| Inter-segment | (122) | (112) | (112) | 9% | 9% |
| Revenue from operations # | 4,517 | 4,417 | 4,117 | 2% | 10% |
| Other income | 53 | 37 | 37 | 42% | 42% |
| TOTAL REVENUE | 4,569 | 4,454 | 4,154 | 3% | 10% |
| EXPENDITURE | | | | | |
| Material & Power costs | 1,514 | 1,567 | 1,548 | -3% | -2% |
| Staff costs | 854 | 765 | 765 | 12% | 12% |
| Research & Development expenses** | 277 | 231 | 231 | 20% | 20% |
| Other expenses | 852 | 776 | 776 | 10% | 10% |
| Manufacturing, staff & other expenses | 3,496 | 3,339 | 3,320 | 5% | 5% |
| EBITDA | 1,073 | 1,115 | 834 | -4% | 29% |
| Interest & Finance charges | 232 | 212 | 212 | 9% | 9% |
| Depreciation & Amortisation | 513 | 436 | 436 | 18% | 18% |
| PBT | 328 | 466 | 185 | -30% | 77% |
| Exceptional item | (80) | 21 | 21 | - | |
| PBT | 248 | 487 | 206 | -49% | 20% |
| Taxes | 72 | 24 | (33) | 200% | -320% |
| Taxes on exceptional item | (23) | 4 | 4 | | |
| NET PROFIT BEFORE MINORITY INTEREST | 199 | 459 | 235 | -57% | -15% |
| Minority interest | 77 | 109 | 109 | -29% | -29% |
| Minority interest on exceptional item | (4) | 6 | 6 | - | |
| NET PROFIT FOR THE PERIOD | 126 | 344 | 120 | -63% | 5% |
| EPS Rs. | 0.8 | 2.9 | 1.0 | | |
| NET PROFIT BEFORE EXCEPTIONAL ITEM | 179 | 333 | 109 | -46% | 64% |
| Exceptional item, net of taxes | (53) | 11 | 11 | | |
| NET PROFIT FOR THE PERIOD | 126 | 344 | 120 | -63% | 5% |
| # Licensing Income | 3 | 8 | 8 | | |
| * Earlier 'Research Services' | | | | | |
| ** Gross Research & Development expenses | 277 | 231 | 231 | | |

| BIOCON LIMITED (CONSOLIDATED) | | | |
|---|-----------------|-----------------|-------------------|
| PROFIT & LOSS STATEMENT | | | (Rs. Crores) |
| Particulars | Q4 FY 26 | Q3 FY 26 | Variance % |
| <u>INCOME</u> | | | |
| Generics | 847 | 851 | -1% |
| Biosimilars | 2,756 | 2,497 | 10% |
| CRDMO* | 1,037 | 917 | 13% |
| Inter-segment | (122) | (92) | 33% |
| Revenue from operations # | 4,517 | 4,173 | 8% |
| Other income | 53 | 117 | -55% |
| TOTAL REVENUE | 4,569 | 4,290 | 6% |
| <u>EXPENDITURE</u> | | | |
| Material & Power costs | 1,514 | 1,441 | 5% |
| Staff costs | 854 | 821 | 4% |
| Research & Development expenses** | 277 | 249 | 11% |
| Other expenses | 852 | 828 | 3% |
| Manufacturing, staff & other expenses | 3,496 | 3,340 | 5% |
| EBITDA | 1,073 | 951 | 13% |
| Interest & Finance charges | 232 | 210 | 10% |
| Depreciation & Amortisation | 513 | 515 | 0% |
| PBT BEFORE EXCEPTIONAL ITEM | 328 | 226 | 45% |
| Exceptional item, Net | (80) | (293) | |
| PBT | 248 | (68) | -465% |
| Taxes | 72 | 51 | 42% |
| Taxes on exceptional item | (23) | (67) | |
| NET PROFIT BEFORE MINORITY INTEREST | 199 | (52) | -483% |
| Minority interest | 77 | 51 | 49% |
| Minority interest on exceptional item | (4) | (247) | - |
| NET PROFIT FOR THE PERIOD | 126 | 144 | -12% |
| EPS Rs. | 0.8 | 1.1 | |
| NET PROFIT BEFORE EXCEPTIONAL ITEM | | | |
| | 179 | 124 | 45% |
| Exceptional item | (53) | 20 | |
| NET PROFIT FOR THE PERIOD | 126 | 144 | -12% |
| <i># Licensing Income</i> | 3 | 24 | |
| <i>* Earlier 'Research Services'</i> | | | |
| <i>** Gross Research & Development expenses</i> | 277 | 249 | |

| BIOCON LIMITED (CONSOLIDATED) | | | | | (Rs. Crores) |
|---|---------------|---------------|---|-------------|------------------|
| PROFIT & LOSS STATEMENT | | | | | |
| Particulars | FY 26 | FY 25 | FY 25 Ex-Lena, BFI- divestment gain | Variance % | Variance adj% |
| INCOME | | | | | |
| Generics | 3,168 | 3,017 | 2,717 | 5% | 17% |
| Biosimilars | 10,431 | 9,017 | 9,017 | 16% | 16% |
| CRDMO* | 3,739 | 3,642 | 3,642 | 3% | 3% |
| Inter-segment | (411) | (416) | (416) | -1% | -1% |
| Revenue from operations # | 16,927 | 15,262 | 14,962 | 11% | 13% |
| Other income | 343 | 1,208 | 151 | -72% | 127% |
| TOTAL REVENUE | 17,270 | 16,470 | 15,113 | 5% | 14% |
| EXPENDITURE | | | | | |
| Material & Power costs | 6,117 | 5,575 | 5,556 | 10% | 10% |
| Staff costs | 3,295 | 2,944 | 2,944 | 12% | 12% |
| Research & Development expenses** | 982 | 859 | 859 | 14% | 14% |
| Other expenses | 3,077 | 2,717 | 2,717 | 13% | 13% |
| Manufacturing, staff & other expenses | 13,472 | 12,096 | 12,076 | 11% | 12% |
| EBITDA | 3,798 | 4,374 | 3,036 | -13% | 25% |
| Interest & Finance charges | 990 | 897 | 897 | 10% | 10% |
| Depreciation & Amortisation | 1,957 | 1,687 | 1,687 | 16% | 16% |
| PBT BEFORE EXCEPTIONAL ITEM | 851 | 1,790 | 452 | -52% | 88% |
| Exceptional item, Net | (403) | 97 | 97 | - | |
| PBT | 448 | 1,887 | 549 | -76% | -18% |
| Taxes | 176 | 416 | 128 | -58% | 38% |
| Taxes on exceptional item | (97) | 21 | 21 | - | |
| Deferred tax charge on withdrawal of indexation benefit | - | 20 | 20 | - | |
| NET PROFIT BEFORE MINORITY INTEREST | 369 | 1,429 | 379 | -74% | -3% |
| Minority interest | 239 | 393 | 221 | -39% | 8% |
| Minority interest on exceptional item | (256) | 23 | 23 | - | |
| NET PROFIT FOR THE PERIOD | 386 | 1,013 | 135 | -62% | 186% |
| EPS Rs. | 2.8 | 8.4 | 1.1 | | |
| NET PROFIT BEFORE EXCEPTIONAL ITEM | 436 | 981 | 103 | -56% | 323% |
| Exceptional item, net of taxes | (50) | 32 | 32 | | |
| NET PROFIT FOR THE PERIOD | 386 | 1,013 | 135 | -62% | 186% |
| # Licensing Income | 34 | 34 | 34 | | |
| * Earlier 'Research Services' | | | | | |
| ** Gross Research & Development expenses | 982 | 859 | 859 | | |

| BIOCON LIMITED (CONSOLIDATED) | | |
|---|---------------------|---------------------|
| BALANCE SHEET | | |
| (Rs Crores) | | |
| Particulars | Mar 31, 2026 | Mar 31, 2025 |
| ASSETS | | |
| Non-current assets | | |
| (a) Property, plant and equipment | 9,473 | 8,708 |
| (b) Capital work-in-progress | 4,613 | 4,102 |
| (c) Right-of-use assets | 578 | 604 |
| (d) Goodwill | 18,377 | 16,786 |
| (e) Other intangible assets | 8,058 | 5,865 |
| (f) Intangible assets under development | 2,374 | 4,407 |
| (g) Financial assets | | |
| Investments | 1,089 | 680 |
| Derivative assets | 43 | 187 |
| Other financial assets | 596 | 68 |
| (i) Income tax asset, net | 429 | 371 |
| (j) Deferred tax asset, net | 556 | 258 |
| (k) Other non-current assets | 285 | 475 |
| Non-current assets | 46,471 | 42,511 |
| Current assets | | |
| (a) Inventories | 6,086 | 4,931 |
| (b) Financial assets | | |
| Investments | 690 | 447 |
| Trade receivables | 5,987 | 5,488 |
| Cash and cash equivalents | 2,417 | 3,227 |
| Other bank balances | 777 | 893 |
| Derivative assets | 22 | 96 |
| Other financial assets | 315 | 456 |
| (c) Other current assets | 886 | 748 |
| Current assets | 17,180 | 16,286 |
| TOTAL - ASSETS | 63,651 | 58,797 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| (a) Equity share capital | 811 | 600 |
| (b) Other equity | 33,221 | 21,044 |
| Equity attributable to owners of the Company | 34,032 | 21,644 |
| Non-controlling interests | 2,590 | 6,068 |
| Total Equity | 36,622 | 27,712 |
| Non-current liabilities | | |
| (a) Financial liabilities | | |
| Borrowings | 10,746 | 12,405 |
| Lease liabilities | 537 | 539 |
| Derivative liabilities | 68 | 23 |
| Other financial liabilities | 555 | 2,828 |
| (b) Other non-current liabilities | 481 | 337 |
| (c) Provisions | 330 | 261 |
| (d) Deferred tax liability, net | 243 | 358 |
| Non-current liabilities | 12,960 | 16,751 |
| Current liabilities | | |
| (a) Financial liabilities | | |
| Borrowings | 4,078 | 5,350 |
| Lease liabilities | 72 | 67 |
| Trade payables | 6,772 | 6,549 |
| Derivative liabilities | 248 | 46 |
| Other financial liabilities | 967 | 933 |
| (b) Other current liabilities | 1,260 | 1,024 |
| (c) Provisions | 256 | 192 |
| (d) Income tax liability, net | 416 | 173 |
| Current liabilities | 14,069 | 14,334 |
| TOTAL - EQUITY AND LIABILITIES | 63,651 | 58,797 |